Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Fig. 3

Correlation between OS and PFS in advanced ESCC patients treated using immunochemotherapy. The patient experienced no event during follow-up, including disease progression or death, indicated by a "0". A "1" indicates that the event of interest took place. Abbreviations: EVT, event; PD-1/L1, anti-PD-1 or anti-PD-L1 agents; CI, confidence interval; OS, overall survival; PFS, progression-free survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us